Clinical profile and impact of family history of premature coronary artery disease on clinical outcomes of patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: Analysis from the HORIZONS-AMI Trial

Cardiovascular Revascularization Medicine

Volumn 15, Issue 8, 2014, Pages 375-380

  Ertelt, Konstanze ^a   Généreux, Philippe ^a,b,c   Mintz, Gary S ^a   Brener, Sorin J ^a,d   Kirtane, Ajay J ^a,b   McAndrew, Thomas C ^a   Francese, Dominic P ^a   Ben Yehuda, Ori ^a   Mehran, Roxana ^a,e   Stone, Gregg W ^a,b  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b Department of Medicine   (United States)

^c HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^d NEW YORK METHODIST HOSPITAL   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary artery disease; Heredity; Percutaneous coronary intervention

Indexed keywords

CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ANEMIA; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG ELUTING CORONARY STENT; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; HEART RATE; HUMAN; HYPERLIPIDEMIA; LEUKOCYTE COUNT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; ONSET AGE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PREMATURE CORONARY ARTERY DISEASE; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYSTOLIC BLOOD PRESSURE; AGED; BLOOD; CLINICAL TRIAL (TOPIC); MIDDLE AGED; MYOCARDIAL INFARCTION; PROCEDURES; PROGNOSIS; RISK FACTOR; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RISK FACTORS; STENTS; TREATMENT OUTCOME;

EID: 84920515645     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2014.09.002     Document Type: Article

References (33)

1. Dawber T.R., Meadors G.F., Moore F.E. Epidemiological approaches to heart disease: the Framingham study. Am J Public Health 1951, 41:279-281.
2. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002, 105:310-315.
3. Hippisley-Cox J., Coupland C., Vinogradova Y., Robson J., May M., Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007, 335:136.
4. Woodward M., Brindle P., Tunstall-Pedoe H. SIGN Group on Risk Estimation. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007, 93:172-176.
5. Rizzo M., Barbagallo C.M., Noto D., Pace A., Cefalú A.B., Pernice V., et al. Family history, diabetes and extension of coronary atherosclerosis are strong predictors of adverse events after PTCA: a one-year follow-up study. Nutr Metab Cardiovasc Dis 2005, 15:361-367.
6. Stone G.W., Witzenbichler B., Guagliumi G., Peruga J.Z., Brodie B.R., Dudek D., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
7. Mehran R., Brodie B., Cox D.A., Grines C.L., Rutherford B., Bhatt D.L., et al. The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial: study design and rationale. Am Heart J 2008, 156:44-56.
8. Van't Hof A.W., Liem A., Suryapranata H., Hoorntje J.C., de Boer M.J., Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 1998, 97:2302-2306.
9. Brener S.J., Dizon J.M., Mehran R., Guerchicoff A., Lansky A.J., Farkouh M., et al. Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: analysis from the HORIZONS-AMI trial. Am Heart J 2013, 166:676-683.
10. The TIMI Study Group The Thrombolysis In Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med 1985, 312:932-936.
11. Kirtane A.J., Sandhu P., Mehran R., McEntegart M., Cristea E., Brener S.J., et al. Association between intraprocedural thrombotic events and adverse outcomes after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (a Harmonizing Outcomes With RevasculariZatiON and Stents in Acute Myocardial Infarction [HORIZONS-AMI] Substudy). Am J Cardiol 2014, 113:36-43.
12. Farkouh M.E., Reiffel J., Dressler O., Nikolsky E., Parise H., Cristea E., et al. Relationship between ST-segment recovery and clinical outcomes after primary percutaneous coronary intervention: the HORIZONS-AMI ECG substudy report. Circ Cardiovasc Interv 2013, 6:216-223.
13. Chow C.K., Islam S., Bautista L., Rumboldt Z., Yusufali A., Xie C., et al. Parental history and myocardial infarction risk across the world: the INTERHEART study. J Am Coll Cardiol 2011, 57:619-627.
14. Otaki Y., Gransar H., Berman D.S., Cheng V.Y., Dey D., Lin F.Y., et al. Impact of family history of coronary artery disease in young individuals (from the CONFIRM registry). Am J Cardiol 2013, 111:1081-1086.
15. Schoenenberger A.W., Radovanovic D., Stauffer J.C., Windecker S., Urban P., Niedermaier G., et al. Acute coronary syndromes in young patients: presentation, treatment and outcome. Int J Cardiol 2011, 148:300-304.
16. Sesso H.D., Lee I.M., Gaziano J.M., Rexrode K.M., Glynn R.J., Buring J.E. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation 2001, 104:393-398.
17. Nasir K., Michos E.D., Rumberger J.A., Braunstein J.B., Post W.S., Budoff M.J., et al. Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history. Circulation 2004, 110:2150-2156.
18. Rissanen A.M. Familial occurrence of coronary heart disease: effect of age at diagnosis. Am J Cardiol 1979, 44:60-66.
19. McPherson R., Davies R.W. Inflammation and coronary artery disease: insights from genetic studies. Can J Cardiol 2012, 28:662-666.
20. McPherson R., Pertsemlidis A., Kavaslar N., Stewart A., Roberts R., Cox D.R., et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007, 316:1488-1491.
21. Helgadottir A., Thorleifsson G., Manolescu A., Gretarsdottir S., Blondal T., Jonasdottir A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316:1491-1493.
22. Samani N.J., Erdmann J., Hall A.S., Hengstenberg C., Mangino M., Mayer B., et al. Genomewide association analysis of coronary artery disease. N Engl J Med 2007, 357:443-453.
23. Harismendy O., Notani D., Song X., Rahim N.G., Tanasa B., Heintzman N., et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature 2011, 470:264-268.
24. Schunkert H., Konig I.R., Kathiresan S., Reilly M.P., Assimes T.L., Holm H., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 2011, 43:333-338.
25. Reilly M.P., Li M., He J., Ferguson J.F., Stylianou I.M., Mehta N.N., et al. Identification of ADAMTS7 as a novel locus for coronary atherosclerosis and association of ABO with myocardial infarction in the presence of coronary atherosclerosis: two genome-wide association studies. Lancet 2011, 377:383-392.
26. Davies R.W., Wells G.A., Stewart A.F., Erdmann J., Shah S.H., Ferguson J.F., et al. A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet 2012, 5:217-225.
27. Zernecke A., Shagdarsuren E., Weber C. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008, 28:1897-1908.
28. Halkin A., Singh M., Nikolsky E., Grines C.L., Tcheng J.E., Garcia E., et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005, 45:1397-1405.
29. Morrow D.A., Antman E.M., Charlesworth A., Cairns R., Murphy S.A., de Lemos J.A., et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early ii trial substudy. Circulation 2000, 102:2031-2037.
30. Palmerini T., Brener S.J., Mehran R., Dangas G., Genereux P., Riva D.D., et al. Leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction: the HORIZONS-AMI trial. Circ Cardiovasc Interv 2013, 6:518-526.
31. Palmerini T., Calabrò P., Piscione F., Dangas G., Genereux P., Riva D.D., et al. Impact of GEne Polymorphisms, Platelet REactivity and the SYNTAX Score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS Study. JACC Cardiovasc Interv 2014, [pii: S1936-8798(14)01174-1, Epub ahead of print, in press]. 10.1016/j.jcin.2014.04.020.
32. Li R., Bensen J.T., Hutchinson R.G., Province M.A., Hertz-Picciotto I., Sprafka J.M., et al. Family risk score of coronary heart disease (CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) study and the NHLBI family heart study. Genet Epidemiol 2000, 18:236-250.
33. Murabito J.M., Nam B.H., D'Agostino R.B., Lloyd-Jones D.M., O'Donnell C.J., Wilson P.W. Accurancy of offspring reports of parental cardiovascular disease history: the Framingham Offspring study. Ann Intern Med 2004, 16(140):434-440.